TAFFANY AMBURGEY: Open Payments
NPI 1265998280 · PARIS, KY. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,028 in 109 payments from 24 companies in 2025. Trend: 2023 $1,034 · 2024 $1,331 · 2025 $2,028
Food & beverage: $2,023Education: $6
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 26 | $420 |
| Vanda Pharmaceuticals Inc. | 8 | $230 |
| AstraZeneca Pharmaceuticals LP | 11 | $203 |
| GlaxoSmithKline, LLC. | 10 | $193 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 7 | $120 |
| Axsome Therapeutics, Inc. | 5 | $119 |
| Bayer Healthcare Pharmaceuticals Inc. | 6 | $98 |
| Abbott Laboratories | 3 | $66 |
| Lilly USA, LLC | 4 | $66 |
| Insulet Corporation | 3 | $63 |
Products named: VRAYLAR, HETLIOZ, TRELEGY ELLIPTA, FARXIGA, CAPLYTA, Auvelity, Kerendia, QULIPTA.
Industry payments across KY — which companies pay providers there.
